Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Cannot Escape Congressional Crosshairs

This article was originally published in The Pink Sheet Daily

Executive Summary

House Republicans question Commissioner von Eschenbach on whether Office of Criminal Investigations is the best use of limited resources.

You may also be interested in...



New Age comes to CDER

House Republicans Joe Barton, Texas, and John Shimkus, Illinois, question a $1.5 million sole source contract to the Center for Professional Development firm to improve morale at FDA's Center for Drug Evaluation and Research. In a Dec. 12 letter, they say they are "very concerned about the lack of any justifiable metrics for measuring success" and ask Commissioner Andrew von Eschenbach to explain how the award was made. The congressmen say there is little information about the firm's expertise with this type of project, although the firm's Web site describes work with a contractor who uses "the metaphor of color, symbol, dance and story to help people give meaning to their lives and work.

Merck Announces Major FOB Initiative With Its New Business Unit

Merck BioVentures plans to launch follow-on version of Amgen’s Aranesp by 2012.

Merck Announces Major FOB Initiative With Its New Business Unit

Merck BioVentures plans to launch follow-on version of Amgen’s Aranesp by 2012.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS067200

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel